Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Comparison of sirolimus alone with sirolimus plus tacrolimus in type 1 diabetic recipients of cultured islet cell grafts.

Authors
  • Gillard, Pieter
  • Ling, Zhidong
  • Mathieu, Chantal
  • Crenier, Laurent
  • Lannoo, Matthias
  • Maes, Bart
  • Roep, Bart
  • Gorus, Frans
  • Pipeleers, Daniel
  • Keymeulen, Bart
Type
Published Article
Journal
Transplantation Journal
Publisher
Ovid Technologies (Wolters Kluwer) - Lippincott Williams & Wilkins
Publication Date
Jan 27, 2008
Volume
85
Issue
2
Pages
256–263
Identifiers
DOI: 10.1097/TP.0b013e31815e8926
PMID: 18212631
Source
Medline
License
Unknown

Abstract

SIR monotherapy is not sufficient to suppress rejection after transplantation under ATG, but it can maintain survival of established beta-cell grafts. However, the risk for a SIR-induced proteinuria remains a concern.

Report this publication

Statistics

Seen <100 times